Inflation Reduction Act Expected to Lower Medicare Part D Out-of-Pocket Costs for Specialty Drugs
New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.